These findings together suggest that LASS2 plays a role in inhibiting β-catenin signaling and that a combination of AAV-LASS2 and XAV939 is a promising strategy for overcoming cisplatin resistance in bladder cancer. This evidence concerns the gene CERS2 and urinary bladder carcinoma.